Samuel G. Levy

Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark.

Vensica Medical Ltd. operates as a medical device company. It designs and develops ultrasound catheter for the treatment of bladder cancer. The firm creates a drug delivery platform to the urinary bladder using the VensiCare device, ultrasound cavitation safely and effectively delivers Botox into the bladder wall in a quick, painfree, needlefree procedure in an office setting. The company was founded by Avner Geva in 2013 and is headquartered in Misgav, Israel.

Convergent Capital SA (CC) is a venture capital investment firm established in 2001 and located west of Paris. CC manages the Convergent Technologies FCPR fund. Their international clientele comprises business angels, entrepreneurs, and institutions including public entities and financial institutions.

Convergent Capital SA (CC) is a venture capital investment firm established in 2001 and located west of Paris. CC manages the Convergent Technologies FCPR fund. Their international clientele comprises business angels, entrepreneurs, and institutions including public entities and financial institutions.

Lauxera Capital Partners SAS is an Independent firm founded in 1992 by Samuel G. Levy. Lauxera Capital Partners SAS is headquartered in Paris.

Veranex, Inc. is a tech-enabled service provider that offers a comprehensive platform for the medtech industry. The company is based in Raleigh, NC and has subsidiaries in Sweden, Switzerland, United States, and United Kingdom. The company provides expert guidance for engineering and design, clinical, market access, and regulatory services, enabling accelerated speed to market, controlled development costs, and development risk mitigation. Veranex's holistic approach ensures that all key functional areas are addressed with the highest level of expertise and attention to detail, making it a trusted partner for companies of all sizes. The company was founded in 2021, and Patrick K. Donnelly has been the CEO of the company since 2021.

Vensica Medical Ltd. operates as a medical device company. It designs and develops ultrasound catheter for the treatment of bladder cancer. The firm creates a drug delivery platform to the urinary bladder using the VensiCare device, ultrasound cavitation safely and effectively delivers Botox into the bladder wall in a quick, painfree, needlefree procedure in an office setting. The company was founded by Avner Geva in 2013 and is headquartered in Misgav, Israel.

Lauxera Capital Partners SAS is an Independent firm founded in 1992 by Samuel G. Levy. Lauxera Capital Partners SAS is headquartered in Paris.

Veranex, Inc. is a tech-enabled service provider that offers a comprehensive platform for the medtech industry. The company is based in Raleigh, NC and has subsidiaries in Sweden, Switzerland, United States, and United Kingdom. The company provides expert guidance for engineering and design, clinical, market access, and regulatory services, enabling accelerated speed to market, controlled development costs, and development risk mitigation. Veranex's holistic approach ensures that all key functional areas are addressed with the highest level of expertise and attention to detail, making it a trusted partner for companies of all sizes. The company was founded in 2021, and Patrick K. Donnelly has been the CEO of the company since 2021.

Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark.

Lauxera Capital Partners SAS is an Independent firm founded in 1992 by Samuel G. Levy. Lauxera Capital Partners SAS is headquartered in Paris.

Veranex, Inc. is a tech-enabled service provider that offers a comprehensive platform for the medtech industry. The company is based in Raleigh, NC and has subsidiaries in Sweden, Switzerland, United States, and United Kingdom. The company provides expert guidance for engineering and design, clinical, market access, and regulatory services, enabling accelerated speed to market, controlled development costs, and development risk mitigation. Veranex's holistic approach ensures that all key functional areas are addressed with the highest level of expertise and attention to detail, making it a trusted partner for companies of all sizes. The company was founded in 2021, and Patrick K. Donnelly has been the CEO of the company since 2021.

Veranex, Inc. is a tech-enabled service provider that offers a comprehensive platform for the medtech industry. The company is based in Raleigh, NC and has subsidiaries in Sweden, Switzerland, United States, and United Kingdom. The company provides expert guidance for engineering and design, clinical, market access, and regulatory services, enabling accelerated speed to market, controlled development costs, and development risk mitigation. Veranex's holistic approach ensures that all key functional areas are addressed with the highest level of expertise and attention to detail, making it a trusted partner for companies of all sizes. The company was founded in 2021, and Patrick K. Donnelly has been the CEO of the company since 2021.

Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark.

Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark.

Veranex, Inc. is a tech-enabled service provider that offers a comprehensive platform for the medtech industry. The company is based in Raleigh, NC and has subsidiaries in Sweden, Switzerland, United States, and United Kingdom. The company provides expert guidance for engineering and design, clinical, market access, and regulatory services, enabling accelerated speed to market, controlled development costs, and development risk mitigation. Veranex's holistic approach ensures that all key functional areas are addressed with the highest level of expertise and attention to detail, making it a trusted partner for companies of all sizes. The company was founded in 2021, and Patrick K. Donnelly has been the CEO of the company since 2021.

Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark.

Convergent Capital SA (CC) is a venture capital investment firm established in 2001 and located west of Paris. CC manages the Convergent Technologies FCPR fund. Their international clientele comprises business angels, entrepreneurs, and institutions including public entities and financial institutions.

Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark.

Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark.

Vensica Medical Ltd. operates as a medical device company. It designs and develops ultrasound catheter for the treatment of bladder cancer. The firm creates a drug delivery platform to the urinary bladder using the VensiCare device, ultrasound cavitation safely and effectively delivers Botox into the bladder wall in a quick, painfree, needlefree procedure in an office setting. The company was founded by Avner Geva in 2013 and is headquartered in Misgav, Israel.

Convergent Capital SA (CC) is a venture capital investment firm established in 2001 and located west of Paris. CC manages the Convergent Technologies FCPR fund. Their international clientele comprises business angels, entrepreneurs, and institutions including public entities and financial institutions.

Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark.

Vensica Medical Ltd. operates as a medical device company. It designs and develops ultrasound catheter for the treatment of bladder cancer. The firm creates a drug delivery platform to the urinary bladder using the VensiCare device, ultrasound cavitation safely and effectively delivers Botox into the bladder wall in a quick, painfree, needlefree procedure in an office setting. The company was founded by Avner Geva in 2013 and is headquartered in Misgav, Israel.

Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark.

Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark.